Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study

Suzi Mansour; Rami Harb; Philippe Michel; Sarah Cassandra Raymond; Suzanne Borrhomée

doi:doi:10.11648/j.ajp.20241002.16

Research Article |

| Peer-Reviewed

Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study

Suzi Mansour^*, Rami Harb, Philippe Michel, Sarah Cassandra Raymond, Suzanne Borrhomée

Published in American Journal of Pediatrics (Volume 10, Issue 2)

Received: 19 January 2024 Accepted: 12 February 2024 Published: 28 April 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Antenatal corticosteroid therapy reduces the risk of developing RDS in premature infants. A single complete course of two doses of betamethasone is recommended between 24 weeks and 34 weeks. There are few data on the neonatal effects of an incomplete course of antenatal corticosteroid therapy. The main objective of our study is to evaluate the effectiveness of a complete versus incomplete course of antenatal corticosteroid therapy on the number of doses of surfactant received postnatally. Methods: This is a single-center retrospective study, including 145 newborns with RDS, divided into 2 groups according to the number of doses of antenatal corticosteroid therapy (1 dose; n = 23 and 2 doses; n = 95). Results: The clinical characteristics of the newborns were similar in the 2 groups. The number of doses of surfactants received postnatally and the severity of RDS are not influenced by the number of doses of antenatal corticosteroid therapy. On the other hand, the number of doses of surfactants received is influenced by the term of birth, the presence of an neonatal sepsis and by resuscitation in the delivery room. The severity of RDS is not influenced either by the interval between the last dose of antenatal corticosteroid therapy and delivery, nor by the cause of prematurity. We did not note any statistically significant difference in clinical improvement (duration of intubation, duration of non-invasive ventilation), the need for postnatal corticosteroid therapy and the risk of occurrence of morbidity and mortality (mortality rate, occurrence of BPD, IVH, severe NEC) between the two groups. Conclusion: just like a complete course, an incomplete course of antenatal corticosteroid therapy can also act on the severity of RDS. Prospective randomized studies should be considered for a formal determination of the neonatal effects of a complete versus incomplete course of antenatal corticosteroid therapy, including the trial BETADOSE.

Published in	American Journal of Pediatrics (Volume 10, Issue 2)
DOI	10.11648/j.ajp.20241002.16
Page(s)	81-95
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Antenatal Corticosteroid Therapy, Surfactant, Dose, RDS, BPD

References

[1]	Simonetta Costa, Enrico Zecca, Daniele De Luca, Maria Pia De Carolis, Costantino Romagnoli. Efficacy of a single dose of antenatal corticosteroids on morbidity and mortality of preterm infants. Eur J Obstet Gynecol Reprod Biol. 2007 Apr; 131(2): 154-7.
[2]	Saliba E. Néonatalogie: bases scientifiques. 2017. (Elsevier Masson).
[3]	The American College of Obstetrics and Gynecology. Antenatal Corticosteroid Therapy for Fetal Maturation. Committee Opinion, Number 713, August 2017.
[4]	Xavier Miracle, Gian Carlo Di Renzo, Ann Stark, Avroy Fanaroff, Xavier Carbonell-Estrany, Erich Saling. Guideline for the use of antenatal corticosteroids for fetal maturation. J. Perinat. Med. 36(2008) 191–196.
[5]	Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009; (2): CD007836. PMID: 19370695 https://doi.org/10.1002/14651858.CD007836
[6]	Sen S, Reghu A, Ferguson SD. Efficacy of a single dose of antenatal steroid in surfactant-treated babies under 31 weeks’ gestation. JMatern Fetal Neonatal Med 2002; 12: 298–303. PMID: 12607761 https://doi.org/10.1080/jmf.12.5.298.303
[7]	Clamadieu C, Jarreau PH. Détresses respiratoires du nouveau-né́ (à l'exclusion de la pathologie ORL et Cardiaque), EMC 4-002-R-10; 1996.
[8]	Stéphanie Roberge, Yves Lacasse, SylvieTapp, YvesTremblay, Anneli Kari, Jing Liu, Myriam Fekih, Hussein S. Qublan, Melania M. Amorim, Emmanuel Bujold. Role of Fetal Sex in the Outcome of Antenatal Glucocorticoid Treatment to Prevent Respiratory Distress Syndrome: Systematic Review and Meta-Analysis. Journal of Obstetrics and Gynaecology Canada. Volume 33, Issue 3, March 2011, Pages 216-226. PMID: 21453561 https://doi.org/10.1016/s1701-2163(16)34822-8
[9]	Suzanne L Miller, Mahalia Chai, Jan Loose, Margie Castillo-Meléndez, David W Walker, Graham Jenkin, Euan M Wallace. The effects of maternal betamethasone administration on the intrauterine growth-restricted fetus. Endocrinology 2007; 148(3): 1288–95. 27. PMID: 17158204 https://doi.org/10.1210/en.2006-1058
[10]	Michal J Simchen, Fawaz Alkazaleh, S Lee Adamson, Rory Windrim, Joyce Telford, Joseph Beyene, John Kingdom. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004 Feb; 190(2): 296–304. PMID: 14981365 https://doi.org/10.1016/j.ajog.2003.08.011
[11]	Andrew Elimian, Reinaldo Figueroa, Alan R Spitzer, Paul L Ogburn, Vandy Wiencek, J Gerald Quirk. Antenatal corticosteroids: are incomplete courses beneficial? Obstet Gynecol. 2003 Aug; 102(2): 352-5. PMID: 12907112 https://doi.org/10.1016/s0029-7844(03)00485-x
[12]	Chee-Ming Huang, Wu-Shiun Hsieh, Chien-Yi Chen, Po-Nien Tsao, Hung-Chieh Chou. Could Premature Infants Benefit from Single Dose Antenatal Betamethason. Research Gate. PMID: 23711674 https://doi.org/10.1016/j.pedneo.2013.04.005
[13]	F. M. Regazzi, L. C. G. Silva, C. F. Lúcio, G. A. L. Veiga, D. S. R. Angrimani, C. I. Vannucchi. Morphometric and functional pulmonary changes of premature neonatal puppies after antenatal corticoid therapy. Theriogenology Volume 153, 1 September 2020, Pages 19-26 PMID: 32417607 https://doi.org/10.1016/j.theriogenology.2020.05.005
[14]	D Roberts, S Dalziel. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19; (3): CD004454. PMID: 33368142 PMCID: PMC8094626 https://doi.org/10.1002/14651858.CD004454.pub4
[15]	T Lacaze-Masmonteil. Prenatal corticotherapy and acceleration of fetal maturation. Experimental and pharmacological data. Arch Pediatr. 1996 Nov; 3(11): 1111-7. PMID: 8952777 https://doi.org/10.1016/s0929-693x(96)89519-4
[16]	Barbara J Stoll, Nellie I Hansen, Rosemary D Higgins, Eunice Kennedy Shriver. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010 Sep; 126(3): 443-56. PMID: 20732945 PMCID: PMC2982806 https://doi.org/10.1542/peds.2009-2959
[17]	Alana J Westover, Timothy J M Moss. Effects of intrauterine infection or inflammation on fetal lung development. Clin Exp Pharmacol Physiol. 2012 Sep; 39(9): 824-30 PMID: 22816773 https://doi.org/10.1111/j.1440-1681.2012.05742.x
[18]	Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics. 2014; 133(1): 171-174.
[19]	Walter-Nicolet E, Courtois E, Milesi C, et al. Premedication practices for delivery room intubations in premature infants in France: Results from the EPIPAGE 2 cohort study. PLoS One. 2019; 14(4): e0215150. https://doi.org/10.1371/journal.pone.0215150
[20]	Pladys P, Berneau P, Beuchée A. Modalités non invasives d’instillation du surfactant exogène. /data/revues/0929693X/v22i5sS1/S0929693X15300518/ [Internet]. 2015 Jun 23; PMID: 26112542 https://doi.org/10.1016/S0929-693X(15)30051-8
[21]	Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019; 115(4): 432-450. PMID: 36863329 PMCID: PMC10064400 https://doi.org/10.1159/000528914
[22]	Stevens TP, Harrington EW, Blennow M et al. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007; (4): CD003063. PMID: 17943779 PMCID: PMC8554819 https://doi.org/10.1002/14651858.CD003063.pub3
[23]	Kanmaz HG, Erdeve O, Canpolat FE et al. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013; 131(2): e502-e509. PMID: 23359581 https://doi.org/10.1542/peds.2012-0603
[24]	Aldana-Aguirre JC, Pinto M, Featherstone RM et al. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2017; 102(1): F17-F23. PMID: 27852668 https://doi.org/10.1136/archdischild-2015-310299
[25]	S J Stock, A J Thomson, S Papworth Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality Green–top Guideline No. 7 October 2010. Royal College of Obstetricians and Gynaecologists. PMID: 35172391 https://doi.org/10.1111/1471-0528.17027
[26]	M Kinalski, A Sledziewski, A Kretowski. Intrauterine stimulation for fetal respiratory system maturation; benefits and risks. Wiad Lek. 2000; 53(9-10): 538-45 PMID: 11148922.
[27]	D Roberts, S Dalziel. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; (3): CD004454. PMID: 16856047 https://doi.org/10.1002/14651858.CD004454.pub2
[28]	Natalia Saldaña-García, María Gracia Espinosa-Fernández, Celia Gómez-Robles et al. Benefits of a Single Dose of Betamethasone in Imminent Preterm Labour. J Clin Med. 2022 Jan; 11(1): 20. PMID: 35011761 PMCID: PMC8745219 https://doi.org/10.3390/jcm11010020
[29]	David M Haas, William McCullough, Michael F McNamara, Cara Olsen. The first 48 hours: Comparing 12-hour and 24-hour betamethasone dosing when preterm deliveries occur rapidly. J Matern Fetal Neonatal Med. 2006 Jun; 19(6): 365-9. PMID: 16801314 https://doi.org/10.1080/14767050600715873
[30]	Joonho Lee, Hyo Suk Seong. Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in "indicated" than in "spontaneous" preterm birth. J Perinat Med. 2009; 37(1): 53-8. PMID: 19099368 PMCID: PMC2887663 https://doi.org/10.1515/JPM.2009.036
[31]	Fernanda Machado Regazzi, Beatriz Melo Justo. Prenatal or postnatal corticosteroids favor clinical, respiratory, metabolic outcomes and oxidative balance of preterm lambs corticotherapy for premature neonatal lambs. Theriogenology, Volume 182, 1 April 2022, Pages 129-137. PMID: 35168015 https://doi.org/10.1016/j.theriogenology.2022.02.006
[32]	Tridente A, De Martino L, De Luca D. Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes. Respir Res. 2019; 20(1): 28. PMID: 30728009 PMCID: PMC6366095 https://doi.org/10.1186/s12931-019-0979-0
[33]	Lamboley-Gilmert G, Lacaze-Masmonteil T; Neonatologists of the Curosurf Postmarketing French Study. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study. Paediatr Drugs. 2003; 5(9): 639-645. PMID: 12956620 https://doi.org/10.2165/00148581-200305090-00006
[34]	O Baud, L Foix-L'Helias, M Kaminski et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999 Oct 14; 341(16): 1190-6. PMID: 10519896 https://doi.org/10.1056/NEJM199910143411604
[35]	W I Anyaegbunam, A B Adetona. Use of antenatal corticosteroids for fetal maturation in preterm infants. Am Fam Physician. 1997 Sep 15; 56(4): 1093-6 PMID: 9310061.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mansour, S., Harb, R., Michel, P., Raymond, S. C., Borrhomée, S. (2024). Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. American Journal of Pediatrics, 10(2), 81-95. https://doi.org/10.11648/j.ajp.20241002.16

Copy | Download

ACS Style

Mansour, S.; Harb, R.; Michel, P.; Raymond, S. C.; Borrhomée, S. Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. Am. J. Pediatr. 2024, 10(2), 81-95. doi: 10.11648/j.ajp.20241002.16

Copy | Download

AMA Style

Mansour S, Harb R, Michel P, Raymond SC, Borrhomée S. Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. Am J Pediatr. 2024;10(2):81-95. doi: 10.11648/j.ajp.20241002.16

Copy | Download

@article{10.11648/j.ajp.20241002.16,
  author = {Suzi Mansour and Rami Harb and Philippe Michel and Sarah Cassandra Raymond and Suzanne Borrhomée},
  title = {Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study
},
  journal = {American Journal of Pediatrics},
  volume = {10},
  number = {2},
  pages = {81-95},
  doi = {10.11648/j.ajp.20241002.16},
  url = {https://doi.org/10.11648/j.ajp.20241002.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20241002.16},
  abstract = {Introduction: Antenatal corticosteroid therapy reduces the risk of developing RDS in premature infants. A single complete course of two doses of betamethasone is recommended between 24 weeks and 34 weeks. There are few data on the neonatal effects of an incomplete course of antenatal corticosteroid therapy. The main objective of our study is to evaluate the effectiveness of a complete versus incomplete course of antenatal corticosteroid therapy on the number of doses of surfactant received postnatally. Methods: This is a single-center retrospective study, including 145 newborns with RDS, divided into 2 groups according to the number of doses of antenatal corticosteroid therapy (1 dose; n = 23 and 2 doses; n = 95). Results: The clinical characteristics of the newborns were similar in the 2 groups. The number of doses of surfactants received postnatally and the severity of RDS are not influenced by the number of doses of antenatal corticosteroid therapy. On the other hand, the number of doses of surfactants received is influenced by the term of birth, the presence of an neonatal sepsis and by resuscitation in the delivery room. The severity of RDS is not influenced either by the interval between the last dose of antenatal corticosteroid therapy and delivery, nor by the cause of prematurity. We did not note any statistically significant difference in clinical improvement (duration of intubation, duration of non-invasive ventilation), the need for postnatal corticosteroid therapy and the risk of occurrence of morbidity and mortality (mortality rate, occurrence of BPD, IVH, severe NEC) between the two groups. Conclusion: just like a complete course, an incomplete course of antenatal corticosteroid therapy can also act on the severity of RDS. Prospective randomized studies should be considered for a formal determination of the neonatal effects of a complete versus incomplete course of antenatal corticosteroid therapy, including the trial BETADOSE.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study

AU  - Suzi Mansour
AU  - Rami Harb
AU  - Philippe Michel
AU  - Sarah Cassandra Raymond
AU  - Suzanne Borrhomée
Y1  - 2024/04/28
PY  - 2024
N1  - https://doi.org/10.11648/j.ajp.20241002.16
DO  - 10.11648/j.ajp.20241002.16
T2  - American Journal of Pediatrics
JF  - American Journal of Pediatrics
JO  - American Journal of Pediatrics
SP  - 81
EP  - 95
PB  - Science Publishing Group
SN  - 2472-0909
UR  - https://doi.org/10.11648/j.ajp.20241002.16
AB  - Introduction: Antenatal corticosteroid therapy reduces the risk of developing RDS in premature infants. A single complete course of two doses of betamethasone is recommended between 24 weeks and 34 weeks. There are few data on the neonatal effects of an incomplete course of antenatal corticosteroid therapy. The main objective of our study is to evaluate the effectiveness of a complete versus incomplete course of antenatal corticosteroid therapy on the number of doses of surfactant received postnatally. Methods: This is a single-center retrospective study, including 145 newborns with RDS, divided into 2 groups according to the number of doses of antenatal corticosteroid therapy (1 dose; n = 23 and 2 doses; n = 95). Results: The clinical characteristics of the newborns were similar in the 2 groups. The number of doses of surfactants received postnatally and the severity of RDS are not influenced by the number of doses of antenatal corticosteroid therapy. On the other hand, the number of doses of surfactants received is influenced by the term of birth, the presence of an neonatal sepsis and by resuscitation in the delivery room. The severity of RDS is not influenced either by the interval between the last dose of antenatal corticosteroid therapy and delivery, nor by the cause of prematurity. We did not note any statistically significant difference in clinical improvement (duration of intubation, duration of non-invasive ventilation), the need for postnatal corticosteroid therapy and the risk of occurrence of morbidity and mortality (mortality rate, occurrence of BPD, IVH, severe NEC) between the two groups. Conclusion: just like a complete course, an incomplete course of antenatal corticosteroid therapy can also act on the severity of RDS. Prospective randomized studies should be considered for a formal determination of the neonatal effects of a complete versus incomplete course of antenatal corticosteroid therapy, including the trial BETADOSE.

VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Suzi Mansour

Department of Neonatology, NOVO Hospital, Pontoise, France

Contact Email
Rami Harb

Department of Neonatology, NOVO Hospital, Pontoise, France

Contact Email
Philippe Michel

Department of Neonatology, NOVO Hospital, Pontoise, France

Contact Email
Sarah Cassandra Raymond

Department of Neonatology, NOVO Hospital, Pontoise, France

Contact Email
Suzanne Borrhomée

Department of Neonatology, NOVO Hospital, Pontoise, France

Contact Email

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mansour, S., Harb, R., Michel, P., Raymond, S. C., Borrhomée, S. (2024). Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. American Journal of Pediatrics, 10(2), 81-95. https://doi.org/10.11648/j.ajp.20241002.16

Copy | Download

ACS Style

Mansour, S.; Harb, R.; Michel, P.; Raymond, S. C.; Borrhomée, S. Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. Am. J. Pediatr. 2024, 10(2), 81-95. doi: 10.11648/j.ajp.20241002.16

Copy | Download

AMA Style

Mansour S, Harb R, Michel P, Raymond SC, Borrhomée S. Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study. Am J Pediatr. 2024;10(2):81-95. doi: 10.11648/j.ajp.20241002.16

Copy | Download

@article{10.11648/j.ajp.20241002.16,
  author = {Suzi Mansour and Rami Harb and Philippe Michel and Sarah Cassandra Raymond and Suzanne Borrhomée},
  title = {Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study
},
  journal = {American Journal of Pediatrics},
  volume = {10},
  number = {2},
  pages = {81-95},
  doi = {10.11648/j.ajp.20241002.16},
  url = {https://doi.org/10.11648/j.ajp.20241002.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20241002.16},
  abstract = {Introduction: Antenatal corticosteroid therapy reduces the risk of developing RDS in premature infants. A single complete course of two doses of betamethasone is recommended between 24 weeks and 34 weeks. There are few data on the neonatal effects of an incomplete course of antenatal corticosteroid therapy. The main objective of our study is to evaluate the effectiveness of a complete versus incomplete course of antenatal corticosteroid therapy on the number of doses of surfactant received postnatally. Methods: This is a single-center retrospective study, including 145 newborns with RDS, divided into 2 groups according to the number of doses of antenatal corticosteroid therapy (1 dose; n = 23 and 2 doses; n = 95). Results: The clinical characteristics of the newborns were similar in the 2 groups. The number of doses of surfactants received postnatally and the severity of RDS are not influenced by the number of doses of antenatal corticosteroid therapy. On the other hand, the number of doses of surfactants received is influenced by the term of birth, the presence of an neonatal sepsis and by resuscitation in the delivery room. The severity of RDS is not influenced either by the interval between the last dose of antenatal corticosteroid therapy and delivery, nor by the cause of prematurity. We did not note any statistically significant difference in clinical improvement (duration of intubation, duration of non-invasive ventilation), the need for postnatal corticosteroid therapy and the risk of occurrence of morbidity and mortality (mortality rate, occurrence of BPD, IVH, severe NEC) between the two groups. Conclusion: just like a complete course, an incomplete course of antenatal corticosteroid therapy can also act on the severity of RDS. Prospective randomized studies should be considered for a formal determination of the neonatal effects of a complete versus incomplete course of antenatal corticosteroid therapy, including the trial BETADOSE.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Complete Versus Incomplete Antenatal Corticosteroid Therapy and Number of Doses of Surfactant Used Posnatally: A Single-Center Study

AU  - Suzi Mansour
AU  - Rami Harb
AU  - Philippe Michel
AU  - Sarah Cassandra Raymond
AU  - Suzanne Borrhomée
Y1  - 2024/04/28
PY  - 2024
N1  - https://doi.org/10.11648/j.ajp.20241002.16
DO  - 10.11648/j.ajp.20241002.16
T2  - American Journal of Pediatrics
JF  - American Journal of Pediatrics
JO  - American Journal of Pediatrics
SP  - 81
EP  - 95
PB  - Science Publishing Group
SN  - 2472-0909
UR  - https://doi.org/10.11648/j.ajp.20241002.16
AB  - Introduction: Antenatal corticosteroid therapy reduces the risk of developing RDS in premature infants. A single complete course of two doses of betamethasone is recommended between 24 weeks and 34 weeks. There are few data on the neonatal effects of an incomplete course of antenatal corticosteroid therapy. The main objective of our study is to evaluate the effectiveness of a complete versus incomplete course of antenatal corticosteroid therapy on the number of doses of surfactant received postnatally. Methods: This is a single-center retrospective study, including 145 newborns with RDS, divided into 2 groups according to the number of doses of antenatal corticosteroid therapy (1 dose; n = 23 and 2 doses; n = 95). Results: The clinical characteristics of the newborns were similar in the 2 groups. The number of doses of surfactants received postnatally and the severity of RDS are not influenced by the number of doses of antenatal corticosteroid therapy. On the other hand, the number of doses of surfactants received is influenced by the term of birth, the presence of an neonatal sepsis and by resuscitation in the delivery room. The severity of RDS is not influenced either by the interval between the last dose of antenatal corticosteroid therapy and delivery, nor by the cause of prematurity. We did not note any statistically significant difference in clinical improvement (duration of intubation, duration of non-invasive ventilation), the need for postnatal corticosteroid therapy and the risk of occurrence of morbidity and mortality (mortality rate, occurrence of BPD, IVH, severe NEC) between the two groups. Conclusion: just like a complete course, an incomplete course of antenatal corticosteroid therapy can also act on the severity of RDS. Prospective randomized studies should be considered for a formal determination of the neonatal effects of a complete versus incomplete course of antenatal corticosteroid therapy, including the trial BETADOSE.

VL  - 10
IS  - 2
ER  -

Copy | Download